查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1344323

癌症个人化医疗市场：按产品、最终用户：2023-2032 年全球机会分析与产业预测

Personalized Cancer Medicine Market By Product (Personalized Medicine Therapeutics, Personalized Medicine Diagnostics), By End User (Hospitals and clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 209 Pages | 商品交期: 2-3个工作天内

价格

2022年癌症个人化医疗市值为1799.9亿美元，预计2023年至2032年复合年增长率为10.9%，到2032年达到5072亿美元。

个人化癌症医学市场-IMG1

癌症个人化医疗市场的成长受到多种因素的推动，包括癌症盛行率的上升以及由此带来的对有效治疗方案的需求不断增长。这是一个重要因素。 精准医学已成为一种有前途的癌症治疗方法，推动了其采用和成长。 此外，人口老化也是推动精准医疗需求的因素之一。 人口老化更有可能罹患癌症，从而产生了更多的潜在患者。 此外，生物技术和基因工程的进步使得更有针对性和个性化的癌症治疗方法的开发成为可能，从而推动了市场的成长。 此外，个人化药物在临床试验中显示出有希望的结果，导致研发活动投资增加。

此外，主要市场参与者采取的更多关键策略（例如产品发布、协议和联盟）将进一步推动预测期内的市场成长。 例如，2021年2月，Qiagen和生物技术公司Inovio Pharmaceuticals宣布建立新的基础合作伙伴关係，开发基于下一代定序（NGS）技术的液体活检伴随诊断产品，以补充Inovio的疗法。将扩大他们的合作伙伴关係。

此外，越来越多的监管审批也为市场成长提供了机会。 例如，2021 年 10 月，全球製药和诊断领域的先驱 F. Hoffmann-La Roche AG 在非小细胞肺癌 (NSCLC) 中推出了 VENTANA PD-L1 (SP263) 检测，作为 Tecentriq 的伴随诊断。美国食品药品监察管理局（FDA）批准。 因此，领先製造商采用此类策略可能会增加个人化医疗领域的需求和采用，为市场成长提供利润丰厚的机会。

然而，个人化医疗的高成本正在阻碍个人化医疗市场的成长。 高昂的诊断和治疗费用使经济困难的患者无法承担，并限制了发展中地区的市场成长。 此外，许多患者对个人化医疗概念缺乏了解也是市场的限制因素。 另一方面，政府和非政府组织可能会提高公众对先进医疗保健选择的认识，并增加个人化癌症药物的采用，从而推动预测期内的市场扩张。

目录

第1章简介

第 2 章执行摘要

第3章市场概述

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
      • 癌症盛行率不断上升
      • 对理想治疗药物的需求不断增加
      • 更多采用基于人工智慧 (AI) 的诊断
    • 抑制因素
      • 个人化医疗成本高昂
      • 有限的报销和承保范围
    • 机会
      • 增加个人化癌症医学的研发活动
  • 新冠肺炎 (COVID-19)：市场影响分析

第 4 章癌症个人化医疗市场：副产品

  • 摘要
  • 治疗药物
  • 诊断剂

第 5 章癌症个人化医疗市场：依最终使用者划分

  • 摘要
  • 医院/诊所
  • 其他

第6章个人化癌症药物市场：依地区

  • 摘要
  • 北美
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 澳大利亚
    • 其他亚太地区
  • 拉丁美洲
    • 拉丁美洲
    • 中东/非洲

第7章竞争态势

  • 简介
  • 关键成功策略
  • 10家主要公司的产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 2022 年主要公司的定位

第8章公司简介

  • Abbott Laboratories
  • ARIEL Precision Medicine, Inc.
  • F. Hoffmann-La Roche Ltd.
  • General Electric
  • Aadi Bioscience, Inc.
  • Illumina, Inc.
  • Qiagen NV.
  • Novartis AG
  • Thermo Fisher Scientific Inc.
  • Bristol-Myers Squibb Company
Product Code: A13364

According to a new report published by Allied Market Research, titled, "Personalized Cancer Medicine Market," The personalized cancer medicine market was valued at $179.99 billion in 2022, and is estimated to reach $507.2 billion by 2032, growing at a CAGR of 10.9% from 2023 to 2032.

Personalized Cancer Medicine Market - IMG1

The personalized cancer medicine market growth is being driven by several key factors such as the increase in prevalence of cancer, resulting in a greater demand for effective treatment options. Precision medicine has emerged as a promising approach for treating cancer, thus driving its adoption and growth. In addition, the aging population is another factor that drives the demand for precision medicine. The geriatric population is more prone to developing cancer, creating a larger pool of potential patients. Furthermore, advances in biotechnology and genetic engineering have made it possible to develop more targeted and personalized cancer therapies, which are likely to drive the market growth. In addition, personalized medicines have shown promising results in clinical trials, leading to increased investment in research and development activities.

Moreover, the rise in key strategies adopted by the key market players such as product launch, agreement, and collaborations further drive the growth of the market during the forecast period. For instance, on February 2021, Qiagen and Inovio Pharmaceuticals, a biotechnology company announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion diagnostic products based on next-generation sequencing (NGS) technology to complement INOVIO's therapies.

Furthermore, a rise in approvals from regulatory organizations further provides opportunity for market growth. For instance, on October 2021, F. Hoffmann-La Roche AG , a global pioneer in pharmaceuticals and diagnostics, received U.S. Food and Drug Administration (FDA) approval of the VENTANA PD-L1 (SP263) Assay in non- small cell lung cancer (NSCLC) as a companion diagnostic test for Tecentriq, advancing the company's commitment to guide clinical decision making through innovative, high quality assays that improve patient access to personalized healthcare. Thus, the adoption of such strategies by key manufacturers can potentially increase the demand and adoption of personalized medicine arena and provide lucrative opportunity to market growth.

However, the high cost of personalized medicines hinders the growth of the personalized medicine market. High cost of diagnosis and treatment makes it inaccessible for the patients with poor financial conditions and restrains the market in developing regions. Furthermore, many patients are unaware about the concept of personalized medicines, which acts as a restrain to the market. On the other hand, government and non-government organizations create awareness about the advanced healthcare options among the population, which may increase the adoption of personalized cancer medicines, thus, driving the market expansion during the forecast period.

The personalized cancer medicine market is segmented into product, end user, and region. By product, the market is categorized into personalized medicine diagnostics and personalized medicine therapeutics. By end user, the market is bifurcated into hospitals & clinics and others. Region wise, the market is analyzed across North America (the U.S., Canada), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (Japan, China and rest of Asia-Pacific), and LAMEA (Latin America, Middle East & Africa).

Major key players that operate in the global personalized cancer medicine market are Abbott Laboratories, ARIEL Precision Medicine, Inc., F. Hoffmann-La Roche Ltd., GE Healthcare, Inc, Aadi Bioscience, Inc., Illumina, Inc., Qiagen, Novartis AG, Thermo Fisher Scientific Inc., Bristol-Myers Squibb Company. The key players operating in the market have adopted product approval, agreement, partnership, product launch, and collaboration as their key strategies to expand their product portfolio.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the personalized cancer medicine market analysis from 2022 to 2032 to identify the prevailing personalized cancer medicine market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the personalized cancer medicine market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global personalized cancer medicine market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Product

  • Personalized Medicine Diagnostics
  • Personalized Medicine Therapeutics

By End User

  • Hospitals and clinics
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Latin America
    • Middle East And Africa

Key Market Players:

    • Aadi Bioscience, Inc.
    • Abbott Laboratories
    • ARIEL Precision Medicine, Inc.
    • Bristol-Myers Squibb Company
    • F. Hoffmann-La Roche Ltd.
    • General Electric
    • Illumina, Inc.
    • Novartis AG
    • Qiagen NV.
    • Thermo Fisher Scientific Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
    • 3.3.1. High bargaining power of suppliers
    • 3.3.2. Low threat of new entrants
    • 3.3.3. Low threat of substitutes
    • 3.3.4. Moderate intensity of rivalry
    • 3.3.5. Moderate bargaining power of buyers
  • 3.4. Market dynamics
    • 3.4.1. Drivers
      • 3.4.1.1. Rise in prevalence of cancer
      • 3.4.1.2. Increase in demand for ideal therapeutics for treatment
      • 3.4.1.3. Rise in adoption of Artificial Intelligence (AI) based diagnosis
    • 3.4.2. Restraints
      • 3.4.2.1. High cost of personalized medicine
      • 3.4.2.2. Limited Reimbursement and coverage
    • 3.4.3. Opportunities
      • 3.4.3.1. Increase in R&D activities in personalized cancer medicine
  • 3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Personalized Medicine Therapeutics
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Personalized Medicine Diagnostics
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country

CHAPTER 5: PERSONALIZED CANCER MEDICINE MARKET, BY END USER

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Hospitals and clinics
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Others
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country

CHAPTER 6: PERSONALIZED CANCER MEDICINE MARKET, BY REGION

  • 6.1. Overview
    • 6.1.1. Market size and forecast By Region
  • 6.2. North America
    • 6.2.1. Key trends and opportunities
    • 6.2.2. Market size and forecast, by Product
    • 6.2.3. Market size and forecast, by End User
    • 6.2.4. Market size and forecast, by country
      • 6.2.4.1. U.S.
      • 6.2.4.1.1. Key market trends, growth factors and opportunities
      • 6.2.4.1.2. Market size and forecast, by Product
      • 6.2.4.1.3. Market size and forecast, by End User
      • 6.2.4.2. Canada
      • 6.2.4.2.1. Key market trends, growth factors and opportunities
      • 6.2.4.2.2. Market size and forecast, by Product
      • 6.2.4.2.3. Market size and forecast, by End User
      • 6.2.4.3. Mexico
      • 6.2.4.3.1. Key market trends, growth factors and opportunities
      • 6.2.4.3.2. Market size and forecast, by Product
      • 6.2.4.3.3. Market size and forecast, by End User
  • 6.3. Europe
    • 6.3.1. Key trends and opportunities
    • 6.3.2. Market size and forecast, by Product
    • 6.3.3. Market size and forecast, by End User
    • 6.3.4. Market size and forecast, by country
      • 6.3.4.1. Germany
      • 6.3.4.1.1. Key market trends, growth factors and opportunities
      • 6.3.4.1.2. Market size and forecast, by Product
      • 6.3.4.1.3. Market size and forecast, by End User
      • 6.3.4.2. France
      • 6.3.4.2.1. Key market trends, growth factors and opportunities
      • 6.3.4.2.2. Market size and forecast, by Product
      • 6.3.4.2.3. Market size and forecast, by End User
      • 6.3.4.3. UK
      • 6.3.4.3.1. Key market trends, growth factors and opportunities
      • 6.3.4.3.2. Market size and forecast, by Product
      • 6.3.4.3.3. Market size and forecast, by End User
      • 6.3.4.4. Italy
      • 6.3.4.4.1. Key market trends, growth factors and opportunities
      • 6.3.4.4.2. Market size and forecast, by Product
      • 6.3.4.4.3. Market size and forecast, by End User
      • 6.3.4.5. Spain
      • 6.3.4.5.1. Key market trends, growth factors and opportunities
      • 6.3.4.5.2. Market size and forecast, by Product
      • 6.3.4.5.3. Market size and forecast, by End User
      • 6.3.4.6. Rest of Europe
      • 6.3.4.6.1. Key market trends, growth factors and opportunities
      • 6.3.4.6.2. Market size and forecast, by Product
      • 6.3.4.6.3. Market size and forecast, by End User
  • 6.4. Asia-Pacific
    • 6.4.1. Key trends and opportunities
    • 6.4.2. Market size and forecast, by Product
    • 6.4.3. Market size and forecast, by End User
    • 6.4.4. Market size and forecast, by country
      • 6.4.4.1. Japan
      • 6.4.4.1.1. Key market trends, growth factors and opportunities
      • 6.4.4.1.2. Market size and forecast, by Product
      • 6.4.4.1.3. Market size and forecast, by End User
      • 6.4.4.2. China
      • 6.4.4.2.1. Key market trends, growth factors and opportunities
      • 6.4.4.2.2. Market size and forecast, by Product
      • 6.4.4.2.3. Market size and forecast, by End User
      • 6.4.4.3. Australia
      • 6.4.4.3.1. Key market trends, growth factors and opportunities
      • 6.4.4.3.2. Market size and forecast, by Product
      • 6.4.4.3.3. Market size and forecast, by End User
      • 6.4.4.4. Rest of Asia-Pacific
      • 6.4.4.4.1. Key market trends, growth factors and opportunities
      • 6.4.4.4.2. Market size and forecast, by Product
      • 6.4.4.4.3. Market size and forecast, by End User
  • 6.5. LAMEA
    • 6.5.1. Key trends and opportunities
    • 6.5.2. Market size and forecast, by Product
    • 6.5.3. Market size and forecast, by End User
    • 6.5.4. Market size and forecast, by country
      • 6.5.4.1. Latin America
      • 6.5.4.1.1. Key market trends, growth factors and opportunities
      • 6.5.4.1.2. Market size and forecast, by Product
      • 6.5.4.1.3. Market size and forecast, by End User
      • 6.5.4.2. Middle East And Africa
      • 6.5.4.2.1. Key market trends, growth factors and opportunities
      • 6.5.4.2.2. Market size and forecast, by Product
      • 6.5.4.2.3. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top winning strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

  • 8.1. Abbott Laboratories
    • 8.1.1. Company overview
    • 8.1.2. Key Executives
    • 8.1.3. Company snapshot
    • 8.1.4. Operating business segments
    • 8.1.5. Product portfolio
    • 8.1.6. Business performance
  • 8.2. ARIEL Precision Medicine, Inc.
    • 8.2.1. Company overview
    • 8.2.2. Key Executives
    • 8.2.3. Company snapshot
    • 8.2.4. Operating business segments
    • 8.2.5. Product portfolio
  • 8.3. F. Hoffmann-La Roche Ltd.
    • 8.3.1. Company overview
    • 8.3.2. Key Executives
    • 8.3.3. Company snapshot
    • 8.3.4. Operating business segments
    • 8.3.5. Product portfolio
    • 8.3.6. Business performance
    • 8.3.7. Key strategic moves and developments
  • 8.4. General Electric
    • 8.4.1. Company overview
    • 8.4.2. Key Executives
    • 8.4.3. Company snapshot
    • 8.4.4. Operating business segments
    • 8.4.5. Product portfolio
    • 8.4.6. Business performance
    • 8.4.7. Key strategic moves and developments
  • 8.5. Aadi Bioscience, Inc.
    • 8.5.1. Company overview
    • 8.5.2. Key Executives
    • 8.5.3. Company snapshot
    • 8.5.4. Operating business segments
    • 8.5.5. Product portfolio
    • 8.5.6. Business performance
    • 8.5.7. Key strategic moves and developments
  • 8.6. Illumina, Inc.
    • 8.6.1. Company overview
    • 8.6.2. Key Executives
    • 8.6.3. Company snapshot
    • 8.6.4. Operating business segments
    • 8.6.5. Product portfolio
    • 8.6.6. Business performance
    • 8.6.7. Key strategic moves and developments
  • 8.7. Qiagen NV.
    • 8.7.1. Company overview
    • 8.7.2. Key Executives
    • 8.7.3. Company snapshot
    • 8.7.4. Operating business segments
    • 8.7.5. Product portfolio
    • 8.7.6. Business performance
    • 8.7.7. Key strategic moves and developments
  • 8.8. Novartis AG
    • 8.8.1. Company overview
    • 8.8.2. Key Executives
    • 8.8.3. Company snapshot
    • 8.8.4. Operating business segments
    • 8.8.5. Product portfolio
    • 8.8.6. Business performance
  • 8.9. Thermo Fisher Scientific Inc.
    • 8.9.1. Company overview
    • 8.9.2. Key Executives
    • 8.9.3. Company snapshot
    • 8.9.4. Operating business segments
    • 8.9.5. Product portfolio
    • 8.9.6. Business performance
  • 8.10. Bristol-Myers Squibb Company
    • 8.10.1. Company overview
    • 8.10.2. Key Executives
    • 8.10.3. Company snapshot
    • 8.10.4. Operating business segments
    • 8.10.5. Product portfolio
    • 8.10.6. Business performance

LIST OF TABLES

  • TABLE 01. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 02. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 03. PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 04. GLOBAL PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 05. PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 06. PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($BILLION)
  • TABLE 07. PERSONALIZED CANCER MEDICINE MARKET, BY REGION, 2022-2032 ($BILLION)
  • TABLE 08. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 09. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 10. NORTH AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 11. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 12. U.S. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 13. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 14. CANADA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 15. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 16. MEXICO PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 17. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 18. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 19. EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 20. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 21. GERMANY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 22. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 23. FRANCE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 24. UK PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 25. UK PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 26. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 27. ITALY PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 28. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 29. SPAIN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 30. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 31. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 32. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 33. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 34. ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 35. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 36. JAPAN PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 37. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 38. CHINA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 39. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 40. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 41. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 42. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 43. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 44. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 45. LAMEA PERSONALIZED CANCER MEDICINE MARKET, BY COUNTRY, 2022-2032 ($BILLION)
  • TABLE 46. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 47. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 48. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022-2032 ($BILLION)
  • TABLE 49. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022-2032 ($BILLION)
  • TABLE 50. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 51. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 52. ABBOTT LABORATORIES: PRODUCT SEGMENTS
  • TABLE 53. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 54. ARIEL PRECISION MEDICINE, INC.: KEY EXECUTIVES
  • TABLE 55. ARIEL PRECISION MEDICINE, INC.: COMPANY SNAPSHOT
  • TABLE 56. ARIEL PRECISION MEDICINE, INC.: PRODUCT SEGMENTS
  • TABLE 57. ARIEL PRECISION MEDICINE, INC.: PRODUCT PORTFOLIO
  • TABLE 58. F. HOFFMANN-LA ROCHE LTD.: KEY EXECUTIVES
  • TABLE 59. F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT
  • TABLE 60. F. HOFFMANN-LA ROCHE LTD.: PRODUCT SEGMENTS
  • TABLE 61. F. HOFFMANN-LA ROCHE LTD.: PRODUCT PORTFOLIO
  • TABLE 62. F. HOFFMANN-LA ROCHE LTD.: KEY STRATERGIES
  • TABLE 63. GENERAL ELECTRIC: KEY EXECUTIVES
  • TABLE 64. GENERAL ELECTRIC: COMPANY SNAPSHOT
  • TABLE 65. GENERAL ELECTRIC: SERVICE SEGMENTS
  • TABLE 66. GENERAL ELECTRIC: PRODUCT PORTFOLIO
  • TABLE 67. GENERAL ELECTRIC: KEY STRATERGIES
  • TABLE 68. AADI BIOSCIENCE, INC.: KEY EXECUTIVES
  • TABLE 69. AADI BIOSCIENCE, INC.: COMPANY SNAPSHOT
  • TABLE 70. AADI BIOSCIENCE, INC.: PRODUCT SEGMENTS
  • TABLE 71. AADI BIOSCIENCE, INC.: PRODUCT PORTFOLIO
  • TABLE 72. AADI BIOSCIENCE, INC.: KEY STRATERGIES
  • TABLE 73. ILLUMINA, INC.: KEY EXECUTIVES
  • TABLE 74. ILLUMINA, INC.: COMPANY SNAPSHOT
  • TABLE 75. ILLUMINA, INC.: PRODUCT SEGMENTS
  • TABLE 76. ILLUMINA, INC.: PRODUCT PORTFOLIO
  • TABLE 77. ILLUMINA, INC.: KEY STRATERGIES
  • TABLE 78. QIAGEN NV.: KEY EXECUTIVES
  • TABLE 79. QIAGEN NV.: COMPANY SNAPSHOT
  • TABLE 80. QIAGEN NV.: PRODUCT SEGMENTS
  • TABLE 81. QIAGEN NV.: PRODUCT PORTFOLIO
  • TABLE 82. QIAGEN NV.: KEY STRATERGIES
  • TABLE 83. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 84. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 85. NOVARTIS AG: PRODUCT SEGMENTS
  • TABLE 86. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 87. THERMO FISHER SCIENTIFIC INC.: KEY EXECUTIVES
  • TABLE 88. THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT
  • TABLE 89. THERMO FISHER SCIENTIFIC INC.: PRODUCT SEGMENTS
  • TABLE 90. THERMO FISHER SCIENTIFIC INC.: PRODUCT PORTFOLIO
  • TABLE 91. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 92. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 93. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT SEGMENTS
  • TABLE 94. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO

LIST OF FIGURES

  • FIGURE 01. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF PERSONALIZED CANCER MEDICINE MARKET, 2022-2032
  • FIGURE 03. TOP INVESTMENT POCKETS IN PERSONALIZED CANCER MEDICINE MARKET (2023-2032)
  • FIGURE 04. HIGH BARGAINING POWER OF SUPPLIERS
  • FIGURE 05. LOW THREAT OF NEW ENTRANTS
  • FIGURE 06. LOW THREAT OF SUBSTITUTES
  • FIGURE 07. MODERATE INTENSITY OF RIVALRY
  • FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALPERSONALIZED CANCER MEDICINE MARKET
  • FIGURE 09. PERSONALIZED CANCER MEDICINE MARKET, BY PRODUCT, 2022(%)
  • FIGURE 10. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE THERAPEUTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 11. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR PERSONALIZED MEDICINE DIAGNOSTICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 12. PERSONALIZED CANCER MEDICINE MARKET, BY END USER, 2022(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR HOSPITALS AND CLINICS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF PERSONALIZED CANCER MEDICINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. PERSONALIZED CANCER MEDICINE MARKET BY REGION, 2022
  • FIGURE 16. U.S. PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 17. CANADA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 18. MEXICO PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 19. GERMANY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 20. FRANCE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 21. UK PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 22. ITALY PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 23. SPAIN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 24. REST OF EUROPE PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 25. JAPAN PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 26. CHINA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 27. AUSTRALIA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 28. REST OF ASIA-PACIFIC PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 29. LATIN AMERICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 30. MIDDLE EAST AND AFRICA PERSONALIZED CANCER MEDICINE MARKET, 2022-2032 ($BILLION)
  • FIGURE 31. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 32. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 33. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 34. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 35. COMPETITIVE DASHBOARD
  • FIGURE 36. COMPETITIVE HEATMAP: PERSONALIZED CANCER MEDICINE MARKET
  • FIGURE 37. TOP PLAYER POSITIONING, 2022
  • FIGURE 38. ABBOTT LABORATORIES: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 39. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 40. ABBOTT LABORATORIES: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 41. F. HOFFMANN-LA ROCHE LTD.: SALES REVENUE, 2020-2022 ($MILLION)
  • FIGURE 42. F. HOFFMANN-LA ROCHE LTD.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 43. GENERAL ELECTRIC: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 44. GENERAL ELECTRIC: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 45. GENERAL ELECTRIC: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 46. AADI BIOSCIENCE, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 47. ILLUMINA, INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 48. ILLUMINA, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 49. ILLUMINA, INC.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 50. QIAGEN NV.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 51. QIAGEN NV.: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 52. QIAGEN NV.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 53. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 54. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 55. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
  • FIGURE 56. THERMO FISHER SCIENTIFIC INC.: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 57. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
  • FIGURE 58. THERMO FISHER SCIENTIFIC INC.: REVENUE SHARE BY REGION, 2021 (%)
  • FIGURE 59. BRISTOL-MYERS SQUIBB COMPANY: NET REVENUE, 2020-2022 ($MILLION)
  • FIGURE 60. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE BY REGION, 2022 (%)